WILSON’S DISEASE TREATMENT MARKET ANALYSIS
Recent Development in Wilson’s disease Treatment Market:
For instance, according to data published by AstraZeneca websites, in August 2021 the FoCus Phase III trial in Wilson disease had reported positive high-level results in showing that ALXN1840 met the primary endpoint with a statistically notable advancement in daily mean copper mobilization from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. ALXN1840, oral medicine, had demonstrated three times more copper mobilization than SoC. FoCus is a crucial, Phase III, rater-blinded randomized, multi-center clinical trial manufactured to evaluate the safety and efficacy of ALXN1840 versus SoC in patients with Wilson disease aged 12 years and older. ALXN1840 has been awarded Orphan Drug Designation in the US and EU for Wilson disease treatment.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
